Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.76 +0.56 (+2.14%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Pfizer Stock Drops Today As CFO Steps Down In August ↗
Pfizer shares are slipping Thursday after it announced that Chief Financial Officer Dave Denton will leave the organization. 
Via Benzinga
News headline image
Pfizer Announces Chief Financial Officer Transition
From Pfizer Inc.
Via Business Wire
News headline image
Consumer Watchdog Honors Michael A. Kelly with 2026 Lifetime Legal Achievement Award
June 17, 2026 -- The award recognizes distinguished attorneys and public-interest advocates whose careers have advanced consumer protection, challenged corporate misconduct, and improved public... 
Via 24-7 Press Release
News headline image
3 S&P 500 Stocks Worth Your Attention
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova... 
Via StockStory
Topics Stocks
News headline image
How to Build a Retirement Income Plan That Lasts Through a High-Inflation Decade ↗
If you haven't planned for inflation, and possibly high inflation, your nest egg's purchasing power could shrink alarmingly. 
Via The Motley Fool
Topics Bonds ETFs Economy
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav... 
Via StockStory
Topics Artificial Intelligence
News headline image
Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth ↗
Pfizer's business may be in better shape than investors think. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Have S&P 500 Index Funds, Often Touted as the Best Stock Investments, Become Dangerous? There's a Worrisome Development -- and a Possibly Better Alternative. ↗
The hard-earned dollars you park in a standard S&P 500 index fund may not be distributed the way you think they are. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. ↗
Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe. 
Via The Motley Fool
Topics Bonds Intellectual Property
News headline image
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments. 
Via The Motley Fool
Thursday's session: most active stock in the S&P500 index ↗
Via Chartmill
News headline image
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff. 
Via MarketBeat
Topics Intellectual Property
News headline image
Why Pfizer Stock Popped Today ↗
Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell. 
Via The Motley Fool
News headline image
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up. 
Via The Motley Fool
News headline image
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics... 
Via MarketBeat
News headline image
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears ↗
Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate... 
Via MarketBeat
News headline image
2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 We Brush Off
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study ↗
Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients. 
Via Benzinga
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Hemostat Powder Market Size, Analysis Report By 2035 ↗
The most recent research report on the "Hemostat Powder Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, an 
Via Talk Markets
Topics Economy
News headline image
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
From Pfizer Inc.
Via Business Wire
News headline image
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗
For a solid yield and strong upside potential, this pharmaceutical stock is worth considering. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
3 Dividend Stocks to Buy Hand Over Fist in June ↗
They sport recent dividend yields of 3.25%, 6.7%, and a whopping 7.7%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. ↗
The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems ↗
Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
From Pfizer Inc.
Via Business Wire
News headline image
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data ↗
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where... 
Via MarketBeat
News headline image
2 Cash-Producing Stocks Worth Your Attention and 1 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 ↗
Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting... 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.